Drug Profile
MBI 002
Alternative Names: MBI-002Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Mycenax Biotech
- Class Antibodies; Antineoplastics
- Mechanism of Action Checkpoint kinase stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours